Physician profile
Anil Kumar Jain
NPI 1679539472
$4,367.61
in general payments reported to CMS, 2019-2025
27 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $237 · 2021: $380 · 2022: $827 · 2023: $700 · 2024: $1,006 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Education: $39.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.18 |
| Education | $39.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,121.93 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $508.08 | 2019-2024 | Veltassa, Korsuva |
| Ani Pharmaceuticals, INC. | $418.99 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $276.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $262.07 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $254.61 | 2019-2024 | Crit-Line, Velphoro, 2008t Bluestar Hemodialysis Machine |
| Novartis Pharmaceuticals Corporation | $219.52 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $206.16 | 2020-2025 | Terlivaz, Acthar |
| Amgen INC. | $162.00 | 2019-2025 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.25 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $121.09 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $112.22 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $93.94 | 2022-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $91.30 | 2019 | |
| Calliditas Therapeutics US INC. | $69.42 | 2025 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.86 | 2024 | Jardiance, Zepbound, Mounjaro |
| Travere Therapeutics, INC. | $44.49 | 2025 | |
| Alexion Pharmaceuticals, INC. | $42.88 | 2019-2022 | |
| Horizon Therapeutics Plc | $28.59 | 2023 | Krystexxa |
| Ascendis Pharma Endocrinology INC | $22.19 | 2025 | Yorvipath |
| Shield Therapeutics INC | $19.67 | 2023 | Accrufer |
| Scpharmaceuticals INC. | $16.97 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.33 | 2019 | |
| Genzyme Corporation | $15.95 | 2025 | |
| Akebia Therapeutics INC | $15.43 | 2021 | |
| Baxter Healthcare | $14.69 | 2019 | |
| Rockwell Medical, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.